---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-217376"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:33:59.941677+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M

## Summary
- Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.
- Operating loss $0.9M vs operating income $3.8M in Q2 2021; net loss $0.7M vs prior net income $2.7M.
- Adjusted EBITDA $4.8M flat YoY; installed base 1,356 instruments (130 placed in quarter).
- Full-year 2022 revenue guidance reaffirmed: closer to high end of $160M-$168M range.
- Received CE mark for cFluor reagents and TBNK kit for European clinical market.

## SEC filing metadata
- accession: 0001193125-22-217376
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312522217376/0001193125-22-217376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312522217376/d363001d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-217376
- JSON: https://secwatch.observer/filing/0001193125-22-217376.json
- Plain text: https://secwatch.observer/filing/0001193125-22-217376.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.